DocCheck Stock

DocCheck EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of DocCheck (AJ91.DE) as of Aug 15, 2026 is 8.93. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 10.51 — a change of -15.01% (lower).

EV/EBIT

8.93

YoY

-15.01%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of DocCheck is 2026 8.93 . EV/EBIT (Enterprise Value to EBIT) of DocCheck was 2025 10.51 . It decreases by -15.01% lower compared to the previous year.

The DocCheck EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
9.45 base
Jan 1, 2019
10.03 base
Jan 1, 2020
8.78 base
Jan 1, 2021
9.40 base
Jan 1, 2022
6.99 base
Jan 1, 2023
13.11 base
Jan 1, 2024
6.55 base
Jan 1, 2025
8.27 base
YEARPRICE-TO-EBIT
2025 8.27
2024 6.55
2023 13.11
2022 6.99
2021 9.40
2020 8.78
2019 10.03
2018 9.45
2017 14.32
2016 9.28
2015 8.52
2014 75.52
2013 11.43
2012 14.54
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

DocCheck Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides DocCheck's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates DocCheck's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots DocCheck's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if DocCheck grows earnings faster than its peers.

DocCheck Stock analysis

What does DocCheck do? DocCheck AG is a German company that was established in Cologne in 1996. It is the largest European specialist portal for medical professionals and provides various products and services for doctors, pharmacists, and pharmaceutical professionals. Initially, the company focused primarily on offering continuing education for doctors and job placement in the medical field. However, soon the business model expanded and additional sectors were added. An important pillar of the company is the online portal DocCheck.com. Here, medical professionals can register and gain access to exclusive content including specialized articles, studies, and videos, as well as receive updates and news from the medical field. Additionally, the company offers a wide range of medical workwear and accessories. The products range from disposable gloves to stethoscopes and medical torches. The assortment is regularly updated and expanded. Another important area of focus is job placement in the medical sector. DocCheck is one of the largest providers on the German market for medical job advertisements. Employers can place ads for a fee, and job seekers can find suitable job offers. A special highlight for customers is the so-called DocCheck Flexikon. It is an online lexicon for medical terms, continuously revised and updated by specialists. The Flexikon is also available as a smartphone and tablet app. Overall, DocCheck is a company with a wide range of products and services tailored to the needs of medical professionals. In recent years, the company has become an important partner in the healthcare sector in Germany and Europe, and it has become an essential player in the industry. DocCheck is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DocCheck stock

EV/EBIT (Enterprise Value to EBIT) of DocCheck is 8.93 in 2026.

EV/EBIT (Enterprise Value to EBIT) of DocCheck changed from 10.51 to 8.93, representing a -15.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) DocCheck since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s DocCheck with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — DocCheck

All Key Metrics — DocCheck